The Conversation (0)
Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has submitted a provisional patent application with the United States Patent and Trademark Office (USPTO), for its proprietary photothermal light device, entitled, "ENDOSCOPE WITH EMR OPTICAL FIBER AND THERMAL SENSOR FOR PHOTOTHERMAL THERAPY".
A prototype of Sona's medical laser was engineered in conjunction with Minnetronix Medical to apply non-thermal, 860 nanometer wavelength high intensity infrared laser light. The device has been designed for use with Sona's patented/patent pending biocompatible gold nanorods which efficiently convert the non-thermal light energy into heat. The device has controls to regulate the intensity and duration of the light exposure and to permit a user to monitor and control the temperature generated in tissue. The device is currently being used for the Company's ongoing pre-clinical efficacy study of its Targeted Hyperthermia Therapy cancer treatment at Dalhousie University.
The Company also recently met with a group of leading surgeons and payer representatives in the U.S as part of its second EXCITE International panel discussion. That roundtable evaluation and discussion, together with its recent pre-submission meeting with the U.S. Food and Drug Administration ("FDA"), provided important feedback and guidance to the Company on the development and validation path for its Targeted Hyperthermia Therapy cancer therapy. Sona Nanotech CEO David Regan commented, "Sona's recent roundtable session with its panel of surgeons from leading U.S. academic medical centres and medical payment organizations provided us with invaluable counsel on considerations for both the 'indications for use' for Sona's Targeted Hyperthermia Therapy and the research data that may be required to secure payment codes from payers. This guidance, together with recent feedback received from the FDA, gives us confidence in the appropriateness of our research study pathway and the likelihood of acceptance by physicians and healthcare institutions of our cancer treatment. The Company continues to develop the data on the safety and efficacy of its therapy to support an eventual regulatory submission with its current study at Dalhousie University Medical School."
Finally, the Company recently named Dr. Carman Giacomantonio, MD, MSc., FRCSC, to its Advisory Board. Dr. Giacomantonio is a surgical oncologist and professor of surgery whose research focuses on the mechanism of action of interleukin-2 therapy in the treatment of melanoma and breast and colorectal cancer. Dr. Giacomantonio is the principal investigator for the Company's current pre-clinical efficacy study at Dalhousie University.
Contact:
David Regan, CEO
+1-902-536-1932
david@sonanano.com
About Sona Nanotech Inc.
Sona Nanotech, a nanotechnology life sciences company, is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (41-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion - thus enabling drugs to reach all tumor compartments more effectively. The size, shape, and surface chemistry of the nanorods target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.
Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications of Targeted Hyperthermia Therapy, Sona's preclinical study plans, the potential impact of the planned studies and its product development plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Not for distribution to United States newswire services or for dissemination in the United States
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/202102
